Broadband Pricing

Business

Barrick Bets Big: Doubling Down on Gold, Copper, and Shareholder Returns Amid Price Surge

Barrick Gold Corporation is strategically ramping up gold production to capitalize on high prices while simultaneously expanding its copper portfolio as a long-term hedge. The mining giant is also channeling robust profits back to investors through enhanced dividends and buybacks, following a period of stellar stock performance.

Feb 2, 2026

Business

Beyond the Hype: Four Forces Shaping Crypto Prediction Markets in 2026

As crypto prediction markets surge past $6B in weekly volume, a new phase of growth beckons. Driven by institutional interest, regulatory evolution, and AI integration, these platforms are poised to redefine speculative finance.

Feb 2, 2026

Business

Markets Reel as $10 Trillion Vaporizes from Gold, Silver, and Crypto in Liquidity Scramble

A synchronized plunge in traditional safe havens and digital assets has erased over $10 trillion in value, signaling a broad market reassessment of Federal Reserve policy and global liquidity conditions.

Feb 2, 2026

Business

From Hurricanes to Sentiment: Wintermute Predicts Crypto Prediction Markets Will Upend Insurance by 2026

A new report from crypto market maker Wintermute Ventures forecasts a seismic shift, arguing that blockchain-based prediction markets will begin displacing traditional insurance by making hyper-specific risks tradable. The firm outlines a future where decentralized infrastructure becomes the new clearing layer for a programmable global economy.

Feb 2, 2026

Business

Analysts Flag Potential Undervaluation in Savaria Shares, DCF Model Points to 35% Discount

A discounted cash flow analysis suggests Savaria Corporation's stock may be trading significantly below its intrinsic value, presenting a potential opportunity for investors. However, experts caution that valuation models are only one piece of the investment puzzle.

Feb 2, 2026

Business

Analysts Maintain Cautious Optimism for Colgate-Palmolive Despite Market Underperformance

While Colgate-Palmolive's stock has trailed the S&P 500 over the past year, Wall Street analysts see a resilient business model and strong international presence supporting long-term growth, maintaining a 'Moderate Buy' consensus.

Feb 2, 2026

Business

Wall Street Braces for Warsh Era: Rate Cut Forecasts Hold Steady Amid Fed Leadership Speculation

Major financial institutions Barclays and Morgan Stanley maintain projections for two interest rate cuts in 2024, despite President Trump's nomination of inflation hawk Kevin Warsh to chair the Federal Reserve. Analysts suggest policy continuity in the near term, though Senate confirmation faces political hurdles.

Feb 2, 2026

Business

UPS Navigates a Painful Turnaround: Why Wall Street's Outcast Could Be a Contrarian Bet

As United Parcel Service executes a strategic overhaul focused on profitability over volume, its financials reveal a nascent but promising trend, leading some investors to see a potential rebound on the horizon despite recent stock declines.

Feb 2, 2026

Business

Apple's AI Gambit: Record Quarter Overshadowed by Questions Over Google Partnership

Apple posts a record-breaking quarter driven by iPhone strength, but Wall Street is divided. While some analysts see a massive AI opportunity ahead, others warn that the partnership with Alphabet's Gemini could limit Apple's long-term upside and strategic independence.

Feb 2, 2026

Business

Geopolitical Tremors Eclipse Fundamentals as Dominant Market Force in 2026

A volatile January has underscored a stark shift for investors: political shocks emanating from Washington now pose a greater threat to portfolios than traditional economic or earnings concerns, reshaping risk calculus across global markets.

Feb 2, 2026

Business

Immunocore's Deep Discount: A Value Trap or a Hidden Gem in Biotech?

After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.

Feb 2, 2026

Business

Apple Doubles Down on AI Audio and Foldable Ambitions Amid Supply Chain Pressures

Apple's acquisition of Israeli AI audio startup Q.ai signals a deeper push into biometric wearables, as the tech giant reportedly reshuffles its 2026 roadmap to prioritize premium iPhones—including a long-rumored foldable model—while navigating ongoing component shortages.

Feb 2, 2026

Business

Coastal Financial's Stock Slide Sparks Debate: Is the Pullback a Buying Opportunity or a Warning Sign?

Shares of Coastal Financial (CCB) have retreated sharply from recent highs, reigniting the debate over the fintech-focused bank's premium valuation. While long-term performance remains strong, current momentum is fading, leaving investors to weigh high growth expectations against traditional valuation metrics.

Feb 2, 2026

Business

Equinor Shares Climb, But Analysts Question Valuation Amid Energy Transition

Equinor's stock has gained ground over the past month, yet a detailed fair value analysis suggests the Norwegian energy giant may be trading at a premium. Investors are weighing strong long-term momentum against future headwinds from the green shift.

Feb 2, 2026

Business

Kinsale Capital's Niche Strategy Fuels Robust Growth Amid Valuation Scrutiny

Specialty insurer Kinsale Capital Group continues to outpace broader industry growth in key metrics, driven by its focus on underserved, higher-risk markets. However, its premium valuation and recent stock volatility have intensified debate among investors about its long-term sustainability.

Feb 2, 2026

From Coffee to Cookies: How New Tariffs Are Driving Up Prices on Imported Grocery Staples

Shoppers are bracing for another wave of price increases as new import taxes take effect, targeting a range of everyday items from spirits to seafood. Experts warn the hikes will squeeze household budgets and force tough choices at the supermarket.

Feb 2, 2026

Business

Scholar Rock's Soaring Stock: Is the Biotech's Momentum Justified or Overheated?

Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.

Feb 2, 2026

Business

Lucid's Arctic Triumph: Winter Range Victory Spotlights EV Efficiency Battle

Lucid Air Grand Touring secures the top spot in a grueling Nordic winter range test, providing a much-needed technical validation for the luxury EV maker amidst a challenging market climate.

Feb 2, 2026

Business

GenLogs Secures $60M to Power Next-Gen Supply Chain Intelligence, Drawing on Intelligence Community Tactics

FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.

Feb 2, 2026

Business

Altimmune Secures Analyst Backing as Pemvidutide Advances Toward Phase 3 MASH Trial

Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.

Feb 2, 2026